Waldencast plc Warrant

Obagi Medical presented new clinical research at the 2025 American Society for Dermatologic Surgery Annual Meeting, highlighting pivotal studies on hyaluronic acid fillers and a scalp serum, demonstrating promising results in midface augmentation and scalp health.

Waldencast has acquired Novaestiq Corp. and the U.S. rights to the Saypha® injectable hyaluronic acid gel line, expanding Obagi Medical's portfolio into dermal fillers and positioning the company at the intersection of skincare and aesthetic treatments.